Camargo Enhances Drug Development Services Through Acquisition of Montreal-based InSymbiosis

Camargo Pharmaceutical Services announced that it will acquire InSymbiosis, a Canadian drug development partner which improves how biopharma companies outsource R&D.

This announcement comes after Camargo shared plans earlier this year to expand capabilities and enhance its global presence both organically and through acquisitions.

“Together, we strengthen our ability to help clients reach critical milestones and connect patients to life-changing therapies faster,” said Camargo CEO, Dan Duffy. “InSymbiosis provides powerful results for clients looking to optimize their nonclinical and clinical development programs. Combined with Camargo’s expertise in drug development strategy and regulatory services, this acquisition accelerates our efforts to deliver an industry-leading integrated drug development solution for the global pharma and biotech market.”

Founded in 2005, InSymbiosis is managed by seasoned ex-pharma and contract research organization drug development scientists and executives. Based in Montreal, Canada, the team includes a multidisciplinary drug development group, financial and investment experts, and a strong project management team.

“We started InSymbiosis with a vision to create symbiotic relationships across the healthcare landscape that drive pharmaceutical development forward,” said InSymbiosis CEO, Dean Wenham, Ph.D. “Together with Camargo, we deepen our ability to build and advance these relationships and deliver optimized development programs for our clients.”